1. The document discusses different treatments for relieving congestion in acute heart failure, including diuretics, vasodilators, inotropes, and ultrafiltration.
2. A clinical trial found that higher versus lower doses of intravenous diuretics resulted in similar outcomes for patients with acute heart failure.
3. Nitrates have not been shown to definitively reduce mortality or rehospitalization when used to treat acute heart failure.
4. More aggressive decongestion as measured by hemoconcentration, albumin, and total protein levels was associated with improved outcomes, suggesting the importance of fully relieving congestion.
Ponencia presentada por la Dra. Lina Badimon Maestro en el directo online ‘Estudio ODYSSEY OUTCOMES: los expertos opinan’, realizado el 20 de noviembre de 2018 en la Casa del Corazón
Pesit trial New England Journal of MedicineDr fakhir Raza
first episode of syncope, should we do workup for Pulmonary embolism well simplified criteria D dimer level CT angiogram ventilation perfusion scanning
Hello members...this powerpoint deals with A journal presentation, that aims at highlighting the "Efficacy & safety of Lacosamide in painful diabetic neuropathy patients".
This also elucidates a model of "Journal club presentation" for interested students.
Happy reading!!
:)
Strict Glycemic Control in Critically ill patients: The Demise of another ver...Prof. Mridul Panditrao
Prof. Mridul M. Panditrao tries to explain the pros and cons about the good strategy, whcih became controversial and almost obsolete. He also tries to tract the whole aspect of the phenomenon and reviews/ RCTs/
Strict (Tight) Glycemic control (SGC/TGC), as it is called, was and still is a good strategy. It can be defined as maintenance of the blood glucose level in the range of 80-110 mg /dl. with help of dose variable and intensive insulin therapy (IIT). Since its introduction, there have been conflicting reports of its efficacy and complications. This resulted in slow but steady neglect of this very good idea leading to its almost complete demise.
An effort has been made in this review, to impartially analyze all the available evidence and try to find the reasons for the negative publicity which led to the neglect or worse still, the wrong use of this protocol. Some suggestions for fair and proper implementation of the strategy are put forward.
etc/
Ponencia presentada por la Dra. Lina Badimon Maestro en el directo online ‘Estudio ODYSSEY OUTCOMES: los expertos opinan’, realizado el 20 de noviembre de 2018 en la Casa del Corazón
Pesit trial New England Journal of MedicineDr fakhir Raza
first episode of syncope, should we do workup for Pulmonary embolism well simplified criteria D dimer level CT angiogram ventilation perfusion scanning
Hello members...this powerpoint deals with A journal presentation, that aims at highlighting the "Efficacy & safety of Lacosamide in painful diabetic neuropathy patients".
This also elucidates a model of "Journal club presentation" for interested students.
Happy reading!!
:)
Strict Glycemic Control in Critically ill patients: The Demise of another ver...Prof. Mridul Panditrao
Prof. Mridul M. Panditrao tries to explain the pros and cons about the good strategy, whcih became controversial and almost obsolete. He also tries to tract the whole aspect of the phenomenon and reviews/ RCTs/
Strict (Tight) Glycemic control (SGC/TGC), as it is called, was and still is a good strategy. It can be defined as maintenance of the blood glucose level in the range of 80-110 mg /dl. with help of dose variable and intensive insulin therapy (IIT). Since its introduction, there have been conflicting reports of its efficacy and complications. This resulted in slow but steady neglect of this very good idea leading to its almost complete demise.
An effort has been made in this review, to impartially analyze all the available evidence and try to find the reasons for the negative publicity which led to the neglect or worse still, the wrong use of this protocol. Some suggestions for fair and proper implementation of the strategy are put forward.
etc/
Antagonistas del receptor de la Adenosina A1: nuevo paradigma en el tratamien...guest6ee1ff
VI Reunión Anual de la Sección de insuficiencia Cardiaca y Trasplante 26 y 27 de Junio de 2009 Actividad acreditada por el comité de Acreditación de la Sociedad Española de Cardiología
A journal article analysis ("journal club") I composed of a notable clinical trial during an internship/Advanced Pharmacy Practice Experience (APPE) in a community pharmacy at a hospital.
Effect of hydrocortisone on development of shock amongDr fakhir Raza
effects of hydrocortisone on development of shock among patients with severe sepsis the HYPRESS Randomized Clinical Trial American Medical Association caring for the critically ill patients Surviving sepsis campaign, to determine weather hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock
Trial of decompressive craniectomy for traumatic intracranial hypertension1Dr fakhir Raza
The New England Journal of Medicine, Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension, Extended Glasgow Outcome Scale (GOS-E), vegetative state, lower severe disability, traumatic brain injury, RESCUEicp,
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
1. Congestion in Acute Heart
Failure: Does it Matter How It
Is Relieved?
Peter S. Pang MD MSc
FACEP FAAEM FAHA FACC
Associate Professor | Emergency Medicine
Associate Director | Clinical Research
Affiliated Regenstrief Scientist
3. Congestion
• Symptoms and signs of heart failure drive
admission and re-admission
• Alleviating congestion is a major goal of
therapy
• Failure to decongest adequately is associated
with worse outcomes
Kociol et.al. Circ Heart Failure 2013
Harjola et.al. EJHF 2010
Picano E et.al. Heart Failure Rev 2010
Gheorghiade et.al. EJHF 2010
Mebazaa et.al. Crit Care Med, 2008
10. The National Institute for Health and
Care Excellence (NICE)
Clinical Guidelines
• Do not routinely offer opiates to people with acute heart failure
• Offer intravenous diuretic therapy to people with acute heart failure
• Do not routinely offer nitrates to people with acute heart failure
• If intravenous nitrates are used in specific circumstances, such as for people with
concomitant myocardial ischaemia, severe hypertension or regurgitant aortic or
mitral valve disease, monitor blood pressure closely in a setting where at least
level 2 care can be provided
• Do not offer sodium nitroprusside to people with acute heart failure
• Do not routinely offer inotropes or vasopressors to people with acute heart
failure
• Do not routinely offer ultrafiltration to people with acute heart failure
• Consider ultrafiltration for people with confirmed diuretic resistance
http://www.nice.org.uk/Guidance/CG187
12. Trick Question
Which of the following drugs given during
hospitalization for acute heart failure
definitively reduces mortality and/or re-
hospitalization safely?
A. Loop diuretics
B. Nitroglycerin
C. Dobutamine (or any other inotrope)
18. Secondary Endpoints
Felker et al. N Engl J Med 2011;364:797-805.
1.Dyspnea @ 72 hr
2.Change in weight
3.Net fluid loss
4.Change in NT-proBNP (p=.06)
19.
20. • Objectives: To quantify the effect of different
nitrate preparations (isosorbide dinitrate and
nitroglycerin) and the effect of route of
administration of nitrates on clinical outcome,
and to evaluate the safety and tolerability of
nitrates in the management of AHF.
• Selection criteria: Randomised controlled
trials comparing nitrates with alternative
interventions in the management of AHF in
adults aged 18 and over.
21. Results
• 4 studies (n=634)
• Two included ONLY post-MI
• One excluded MI
• One included both
NO Difference
22. • IV ISDN 3 mg q 5 min (n = 52) vs.
IV furosemide (N = 52) 80 mg q 15 min
– Mean dose ISDN = 11.4 (± 6.8) mg
– Mean dose furosemide = 200 (± 65) mg
Cotter et al. Lancet 1998:351:389-3.
25. Primary: Bivariate change in weight and creatinine at 96 hours.
Followed for 60 days
N=188 patients
Had to have worsening renal function and persistent congestion
1. No differences in weight loss
2. Higher creatinine
3. More serious adverse events
27. • No differences in the co-primary end points of urine
volume and change in cystatin C at 72 hours
• AHF patients, enrolled within 24 hours of
presentation, with eGFR between 15-60
• N=360
29. Suggesting that more aggressive decongestion, defined by
hemoconcentration, albumin, and total protein, was
associated with improved outcomes in patients with AHF
from the ESCAPE trial
Testani et.al. 2010
33. Present & Future
• Destination matters more than the journey
• Measurement
• Tailored (at both the type of congestion and
the reason for congestion)
37. ePAD(mmHg)
Intra-cardiac pressures do
increase prior to HFRE
Zile et al. Circulation 2008 118:1433-1441
Chronicle device
(COMPASS-HF study)
BodyWeight(kg)
In the absence of weight gain!